• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lundquist Investigator Dr. Yoshihara Awarded $3 Million NIH R01 Grant for Diabetes Stem Cell Therapy Research

By: The Lundquist Institute for Biomedical Innovation via GlobeNewswire
April 01, 2024 at 17:52 PM EDT

Torrance, California, April 01, 2024 (GLOBE NEWSWIRE) -- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health, has granted Eiji Yoshihara, PhD, a principal investigator at The Lundquist Institute (TLI) and assistant professor at the David Geffen School of Medicine at UCLA, a five-year grant totaling $3 million. This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.
         
Insulin-dependent diabetes, including autoimmune Type 1 and stress-induced Type 2, presents a significant health burden, often necessitating lifelong insulin therapy and glucose monitoring. While pancreatic islet transplantation offers a ray of hope for Type 1 diabetes, its applicability is hindered by donor shortages and the need for immunosuppression. Dr. Yoshihara's research focuses on the potential of human pluripotent stem cells (hPSCs) to create functional islet cells.

Overcoming the limitations of current stem cell-derived organoids, which are three-dimensional structures that mimic the function of an organ and include functional immaturity and heterogeneity, Dr. Yoshihara’s team aims to discover markers to differentiate mature organoids, optimizing their clinical utility. Furthermore, the research team, led by Dr. Yoshihara, will investigate cutting-edge transcriptional gene regulation processes that are anticipated to accelerate the maturation of organoids.

“Despite significant progress in stem cell-derived mini-organ technologies, we are still challenged by their functional immaturity and variability,” said Dr. Yoshihara. “There are no effective methods to differentiate between mature and immature organoids in dishes. By identifying markers to distinguish these ‘good’ and ‘bad’ organoids and developing techniques to segregate organoids of optimal quality, we aim to propel cell therapy in diabetes into a more promising future.”

Dr. Yoshihara is a renowned expert in stem cell therapy. This innovative research is supported by the NIDDK, committed to generating vital knowledge and developing treatments for chronic and costly diseases, ultimately improving patient care and health outcomes nationwide.

Attachment

  • Lundquist Institute _ Dr. Eiji Yoshihara

Max Benavidez
The Lundquist Institute for Biomedical Innovation
310-200-2682
max.benavidez@lundquist.org

More News

View More
Rocket Lab: A Parabolic Run Meets a Healthy Pullback
July 23, 2025
Via MarketBeat
Tickers RKLB
Falling Fast, Rising Soon? 3 Stocks With Upside Ahead
July 23, 2025
Via MarketBeat
Topics Earnings
Tickers ALLT ARDT GPI
The Top 120 Lesser-Known Affordable Luxury Vacation Spots in the U.S.
July 23, 2025
Via MarketBeat
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
July 23, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers LLY PFE UNH
Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?
July 23, 2025
Via MarketBeat
Topics Earnings
Tickers T TMUS VZ
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap